Q-omics provides the consensus-scored LRRC19 profile across patient tissues and cancer cell-line models. LRRC19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC19 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, LRRC19 RNA expression shows 15,593 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where LRRC19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC19 survival associations across molecular data types. LRRC19 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC19 RNA expression–survival associations across cancer types. High LRRC19 expression shows unfavorable associations in MESO, but favorable associations in KIRC, KIRP, BRCA, OV and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC19 RNA expression.
This table summarizes LRRC19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC19 shows lower tumor expression in COAD, KIRC, KICH, LUAD and KIRP and higher tumor expression in HNSC. The COAD box plot shows higher LRRC19 RNA expression in normal versus tumor tissue (log2 FC = −3.301, t-test p < 0.001).
This table shows molecular features associated with LRRC19 in patient tissues and cancer cell lines. In patient samples, LRRC19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
